14,998 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,998 shares of the biopharmaceutical company's stock, valued at approximately $677,000.

Other hedge funds have also modified their holdings of the company. Smartleaf Asset Management LLC boosted its position in shares of PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 270 shares during the last quarter. Sterling Capital Management LLC lifted its position in PTC Therapeutics by 424.4% during the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 522 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in PTC Therapeutics during the fourth quarter valued at approximately $68,000. R Squared Ltd acquired a new position in PTC Therapeutics during the fourth quarter valued at approximately $79,000. Finally, KBC Group NV lifted its position in PTC Therapeutics by 36.4% during the fourth quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock valued at $137,000 after buying an additional 813 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PTCT shares. JPMorgan Chase & Co. reduced their price target on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Citigroup raised shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and reduced their price target for the company from $50.00 to $40.00 in a research report on Wednesday, May 7th. Cantor Fitzgerald reduced their price target on shares of PTC Therapeutics from $113.00 to $112.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Barclays reduced their price target on shares of PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Finally, StockNews.com raised shares of PTC Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, PTC Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $61.92.

Insider Buying and Selling

In other PTC Therapeutics news, Director Stephanie Okey sold 5,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $54.00, for a total transaction of $270,000.00. Following the sale, the director now directly owns 8,867 shares of the company's stock, valued at approximately $478,818. This represents a 36.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan Steven Jacobson sold 1,230 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $51.52, for a total transaction of $63,369.60. Following the sale, the director now directly owns 19,118 shares in the company, valued at $984,959.36. This trade represents a 6.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,305 shares of company stock worth $1,682,755. Insiders own 5.50% of the company's stock.

PTC Therapeutics Trading Up 0.8%

Shares of NASDAQ:PTCT opened at $46.75 on Thursday. The company has a fifty day simple moving average of $48.62 and a 200 day simple moving average of $47.09. The firm has a market cap of $3.71 billion, a PE ratio of -7.87 and a beta of 0.52. PTC Therapeutics, Inc. has a 12-month low of $28.72 and a 12-month high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $437.16 million. The firm's quarterly revenue was down 9.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.20) EPS. As a group, equities research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.